Overview

Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis

Phase:

Phase 2

Details

Lead Sponsor:

Abbott

Treatments:

Adalimumab
Antibodies
Antibodies, Monoclonal